Home

Subscription

February 2017 issue

January 2017 issue



BACK ISSUES

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006


2016 Issues

December 2016 Issue
• Peace and Good Will
• New Drug Review: Lixisenatide (Adlyxin – Sanofi)
• Appreciation
• Index for Volume 11, 2016


November 2016 Issue
• Feature: You Say Adherence and I Say Compliance – Whatever We Call It, Pharmacists, with Our Patients, Must Respond to this Challenge!
• New Drug Review: Lifitegrast (Xiidra – Shire)


October 2016 Issue
• Feature: Understanding and Reducing Drug Prices Must Start with Transparency
• New Drug Review: Insulin degludec (Tresiba – Novo Nordisk)


September 2016 Issue
• Feature: Our Profession and Our Patients Need Independent Pharmacists! But Can We Keep Them?

August 2016 Issue
• Feature: The PBM Formulary Follies
• New Drug Review: Pimavanserin tartrate (Nuplazid – Acadia)


July 2016 Issue
• Feature: CVS has an Exceptional Opportunity but Rejects It – To the Peril of its Customers and Frustration and Risk of its Pharmacists!
• New Drug Review: Brivaracetam (Briviact – UCB)


June 2016 Issue
• Feature: Physician-Assisted Suicide - Can we not care best for our patients by walking with them in the dying instead of leading them to it?
• New Therapeutic Agents Marketed in the United States in 2015


May 2016 Issue
• Feature: OUTRAGES! – But Some With Opportunities!
• New Drug Review: Lesinurad (Zurampic – AstraZeneca; Ironwood)


April 2016 Issue
• Feature: The FDA Should Provide Pharmacists with the Authority to Dispense Chantix Without a Prescription
• New Drug Review: Cariprazine hydrochloride (Vraylar – Allergan)


March 2016 Issue
• Feature: Prescription Drug Prices – Billions for Pharmaceutical Companies, Insurance Companies, and PBMs, but Pennies for Pharmacies
• New Drug Review: Eluxadoline (Viberzi – Allergan)


February 2016 Issue
• Feature: Is Walgreens Valeant's New Philidor?
• New Drug Review: Mepolizumab (Nucala – GlaxoSmithKline)


January 2016 Issue
• Feature: Pharmacy Must Have a More Effective Organizational Structure! - The United Pharmacists of America
• New Drug Review: Ledipasvir/sofosbuvir (Harvoni – Gilead Sciences)
• New Drug Review: Secukinumab (Cosentyx – Novartis)